These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 23863691)

  • 1. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.
    Alcorn S; Walker AJ; Gandhi N; Narang A; Wild AT; Hales RK; Herman JM; Song DY; Deweese TL; Antonarakis ES; Tran PT
    Int J Mol Sci; 2013 Jul; 14(7):14800-32. PubMed ID: 23863691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeted therapies and radiation therapy in non-small cell lung cancer].
    Rivera S; Quéro L; Wong Hee Kam S; Maylin C; Deutsch E; Hennequin C
    Cancer Radiother; 2011 Oct; 15(6-7):527-35. PubMed ID: 21885318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?
    Baselga J
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii281-8. PubMed ID: 18790967
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.
    Walker AJ; Alcorn SR; Narang AK; Nugent KM; Wild AT; Herman JM; Tran PT
    Curr Probl Cancer; 2013; 37(5):301-12. PubMed ID: 24331186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
    Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Strategies to Improve Targeted Radionuclide Therapy.
    Chan TG; O'Neill E; Habjan C; Cornelissen B
    J Nucl Med; 2020 Nov; 61(11):1544-1552. PubMed ID: 33037092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?
    Riesterer O; Tenzer A; Zingg D; Hofstetter B; Vuong V; Pruschy M; Bodis S
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):361-8. PubMed ID: 14751504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
    Kabakov AE; Kudriavtsev VA; Makarova IuM
    Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.
    George TJ; Franke AJ; Chakravarthy AB; Das P; Dasari A; El-Rayes BF; Hong TS; Kinsella TJ; Landry JC; Lee JJ; Monjazeb AM; Jacobs SA; Raben D; Rahma OE; Williams TM; Wu C; Coleman CN; Vikram B; Ahmed MM
    Cancer; 2019 Aug; 125(16):2732-2746. PubMed ID: 31017664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.
    Hatake K; Tokudome N; Ito Y
    Breast Cancer; 2007; 14(2):132-49. PubMed ID: 17485898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel targeted radiosensitisers in cancer treatment.
    Zaidi SH; Huddart RA; Harrington KJ
    Curr Drug Discov Technol; 2009 Jun; 6(2):103-34. PubMed ID: 19519337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel chemoradiosensitizers for cancer therapy.
    Page P; Yang LX
    Anticancer Res; 2010 Sep; 30(9):3675-82. PubMed ID: 20944153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitization of prostate cancer by soy isoflavones.
    Raffoul JJ; Sarkar FH; Hillman GG
    Curr Cancer Drug Targets; 2007 Dec; 7(8):759-65. PubMed ID: 18220535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.
    Chang L; Graham PH; Hao J; Bucci J; Cozzi PJ; Kearsley JH; Li Y
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):469-96. PubMed ID: 24445654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy.
    Searle EJ; Illidge TM; Stratford IJ
    Clin Oncol (R Coll Radiol); 2014 May; 26(5):266-76. PubMed ID: 24602563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecularly targeted radiosensitization chances towards gene aberration-due organ confined/regionally advanced prostate cancer radioresistance.
    Alberti C
    G Chir; 2015; 36(3):133-6. PubMed ID: 26188759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted radiosensitization in prostate cancer.
    Ghotra VP; Geldof AA; Danen EH
    Curr Pharm Des; 2013; 19(15):2819-28. PubMed ID: 23448469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
    Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
    Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.
    Gravina GL; Marampon F; Sherris D; Vittorini F; Di Cesare E; Tombolini V; Lenzi A; Jannini EA; Festuccia C
    Prostate; 2014 Jun; 74(8):852-68. PubMed ID: 24715588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.